Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities research analysts at Zacks Research raised their Q1 2025 EPS estimates for Nektar Therapeutics in a report issued on Wednesday, April 2nd. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn ($0.17) per share for the quarter, up from their prior forecast of ($0.21). The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics' Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.70) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.84) EPS.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.18) by $0.33. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. The firm had revenue of $29.18 million during the quarter, compared to analyst estimates of $36.65 million.
Several other research firms also recently issued reports on NKTR. HC Wainwright restated a "buy" rating and set a $6.50 price objective on shares of Nektar Therapeutics in a report on Thursday, March 13th. Oppenheimer upgraded shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 price target on the stock in a research note on Friday, March 14th. William Blair reiterated a "market perform" rating on shares of Nektar Therapeutics in a research note on Thursday, March 13th. B. Riley started coverage on shares of Nektar Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $4.00 price objective on the stock. Finally, Jefferies Financial Group upgraded Nektar Therapeutics from a "hold" rating to a "buy" rating and raised their target price for the stock from $1.00 to $2.00 in a research note on Friday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $4.50.
Read Our Latest Analysis on NKTR
Nektar Therapeutics Price Performance
Nektar Therapeutics stock traded up $0.12 during midday trading on Monday, reaching $0.62. The company's stock had a trading volume of 8,020,651 shares, compared to its average volume of 1,834,868. The stock has a market capitalization of $114.96 million, a P/E ratio of -0.74 and a beta of 0.69. The stock's 50-day simple moving average is $0.77 and its 200-day simple moving average is $0.99. Nektar Therapeutics has a 52-week low of $0.43 and a 52-week high of $1.93.
Institutional Trading of Nektar Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the business. Nantahala Capital Management LLC boosted its holdings in Nektar Therapeutics by 90.0% in the fourth quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company's stock valued at $7,263,000 after purchasing an additional 3,700,000 shares during the last quarter. Woodline Partners LP boosted its stake in shares of Nektar Therapeutics by 187.3% in the fourth quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company's stock worth $4,626,000 after buying an additional 3,242,841 shares during the last quarter. Altium Capital Management LLC grew its holdings in Nektar Therapeutics by 26,172.0% during the fourth quarter. Altium Capital Management LLC now owns 3,000,000 shares of the biopharmaceutical company's stock worth $2,790,000 after acquiring an additional 2,988,581 shares during the period. 22NW LP acquired a new stake in Nektar Therapeutics during the fourth quarter worth about $2,038,000. Finally, Peapod Lane Capital LLC purchased a new position in Nektar Therapeutics during the fourth quarter valued at approximately $1,030,000. Institutional investors and hedge funds own 75.88% of the company's stock.
About Nektar Therapeutics
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Further Reading
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
